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WS10.1 Can home drug audit prevent oversupply and indicate
adherence?
C. Whitton1, D. Waine1, M. Goodwin1, K. Donohue1, D. Weston2, C. Stone2,
D. Derry1. 1Derriford Hospital, CF Team, Plymouth, United Kingdom; 2Peninsula
College of Medicine & Dentistry, Plymouth, United Kingdom
Objectives: Following deaths of 2 CF patients, relatives returned drugs valued
€4,443 and €3,631. 1 had >100 days supply of pulmozyme and stocks of 7 drugs
which had date expired. In clinic, CF patients claim non-adherence with drugs
because stocks have run out. In 2014, CF centres in England will take over all
prescription of high cost nebulised drugs (HCND). Would it be cost efﬁcient
to assess home drug stocks to prevent oversupply, wastage and to help assess
adherence?
Methods:We administered a questionnaire and undertook home visits to 27 patients
attending our CF centre to audit their drug stocks.
Results: Patients were prescribed 2−23 drugs (median 13), and held stocks of 2−27
drugs. 1% of all drugs were date expired. 15% drugs were no longer prescribed
(7.7% by value) of which 82% by value were antibiotics. For 19% drugs, patients
held >10 weeks supplies. 37/369 prescriptions were for HCND. For HCND, no
patient held >2 months supply. Patients held no home stocks for 15% of prescribed
drugs. 18/27 patients lacked stocks of at least 1 prescribed drug. Some held no
stocks of 43% of their prescription. Patients held no home stocks for 9/37 (24%)
HCND. Lack of home stocks was not correlated with FEV1 or educational level.
Many patients had poor awareness of levels of stocks. One patient predicted 7 days,
but had median 88 days; another predicted 84 days, but had 7.5 days. 62% patients
reported having previously run out of medications; yet 7/10 patients who reported
never having run out, held no home stocks of at least 1 prescribed drug.
Conclusion: Home drug audits offer no cost savings with HCND. Visits may
identify patients who lack stocks and so are non adherent.
WS10.2 Adherence to study drugs in clinical trials
T. Pugatsch1, D. Shoseyov1, B. Hayut1, E. Kerem1. 1Hadassah Medical Center,
Pediatrics and CF Center, Jerusalem, Israel
Objectives: Clinical trials are all based on the presumption that patients are adherent
to the study protocol. However, no data exists to assess if trial participants are more
adherent to a study drug regimen then to their regular treatment. The aim of this
study was to determine adherence to study drugs by counting used and unused
drugs and compare the result with the number of doses the patient should have
taken over a speciﬁed time period.
Methods: All clinical trials carried out at the Hadassah CF Center over the last
5 years were included. Actual adherence as determined by counted drugs was
analyzed according to drug administration mode, study lengths and number of
study visits. A subset of patients answered a two-part questionnaire covering study
speciﬁc and general treatment speciﬁc issues.
Results: Eight studies with patient numbers varying between 4 and 32 per trial
were analyzed. For 7/8 studies adherence was between 80–100%. No difference was
found between inhalations (solutions, powder) or oral (80–100%) administration.
However, adherence decreased substantially if the patients had to prepare the drugs
themselves (62%). Study length inﬂuenced adherence, the longer the study the worse
the adherence (82% at the beginning, 42% after 36 months). A substantial decrease
was noted over Holiday periods and during the summer months. No correlation was
found between number of study visits and adherence to study drug.
Conclusion: Patients are generally more adhering when taking study drug then for
their regular treatment. However, study length, mode of administration, and timing
according to Holydays and vacation are crucial to the success of a clinical trial.
WS10.3 Adherence with ivacaftor in cystic ﬁbrosis patients with the
G551D mutation
J. Fox1, G.H. Jones1, R. Sapina-Vivo1, E. Phitidis1, M. Ledson1, M. Walshaw2,
J. Greenwood1. 1Liverpool Heart & Chest Hospital, Adult CF Service, Liverpool,
United Kingdom; 2Liverpool Heart & Chest Hospital, Respiratory Medicine,
Liverpool, United Kingdom
Objectives: Ivacaftor is an expensive but potentially curative treatment for CF pa-
tients with the G551D mutation, and concordance with therapy underpins not only
its clinical efﬁcacy but also its continuing prescription. Despite this, a number of
patients have poor adherence, and we wished to study the reasons for this further.
Methods: Dispensing records and case notes for all patients prescribed ivacaftor
were reviewed. Patients were deemed adherent if >80% of ivacaftor prescriptions
were fulﬁlled, and outcomes were compared for corresponding periods before and
after treatment commenced.
Results: Of 17 patients prescribed ivacaftor (6.0% of our clinic), 14 were deemed
adherent (100% prescription fulﬁlment versus 45.4% in the non-adherent group).
Mean duration of treatment was similar in both groups (10.4 vs 9.4 months). The
adherent patients tended to be older and have both a higher level of educational
achievement and socioeconomic status, and had improvement in outcomes (see
table). The non-adherent group had poorer baseline health indicators and showed
little or no improvement following ivacaftor prescription: all had chaotic lifestyles
which had previously impacted on their CF management.
Table: Adherence with ivacaftor
Mean FEV1% BMI Admissions
age Pre Post Pre Post Pre Post
Adherent (n = 14) 27.9 78.6% 91.0% 25.3 25.9 1.1 0.2
Non-adherent (n = 3) 20.3 49.5% 50.0% 18.5 17.7 5.3 3.0
Conclusion: Nearly one ﬁfth of our eligible patients do not take ivacaftor regularly.
This is a reﬂection of their chaotic lifestyles: we are continuously working with these
patients to improve their adherence with what is potentially a lifesaving treatment.
WS10.4 Pharmacist intervention to inﬂuence beliefs about medication
in an adult cystic ﬁbrosis clinic
P.I. Wilson1,2, C.M. Ohri2,3, S.P. Range2,3. 1University Hospitals Leicester,
Pharmacy Department, Leicester, United Kingdom; 2University Hospitals
Leicester, Glenﬁeld Hospital Cystic Fibrosis Unit, Leicester, United Kingdom;
3University Hospitals Leicester, Institute for Lung Health, Leicester, United
Kingdom
Objectives: To use the CF Quality of Life (CFQol) and Beliefs about Medicines
(BMQ) questionnaires to assess the beliefs of patients with CF with a view to
understanding reasons for non-adherence with treatment.
Methods: All 30 patients within the clinic prescribed inhaled antibiotic therapy were
asked to complete CFQoL and BMQ and to undertake a discussion with the CF
pharmacist, designed to educate the patient about their treatment and to identify and
overcome barriers to adherence with therapy. 21 patients were recruited, of these 12
completed pre and post-intervention questionnaires. The results were analysed for
an effect of intervention, gender and CF Trust banding. BMQ data was compared
to published data from other diseases.
Results: Pharmacist intervention demonstrated a statistically signiﬁcant (p = 0.0339)
reduction in the harm domain of the BMQ indicating reduced concern about harm
from medication. Effects on other domains of the BMQ and all domains of the
CFQoL were not statistically signiﬁcant. No statistically signiﬁcant differences
were seen between male and female patients or across different banding levels.
Downwards trends were seen in QoL domains as banding increased with the
exception of “concerns for the future”. BMQ data demonstrated higher perceived
need for medication and lower perceived harm from medication than patients with
other chronic diseases.
Conclusion: Pharmacist intervention improved scores in the BMQ. Improvements
in the BMQ have been associated with higher levels of adherence in other diseases.
People with CF have a greater appreciation for, and lower concerns of harm from
their treatment than people with other chronic diseases.
